Gilead Sciences: Pharmaceutical Prices, Patents, And The FDA – ValueWalk Premium

Gilead Sciences: Pharmaceutical Prices, Patents, And The FDA

Gilead Sciences: Pharmaceutical Prices, Patents, And The FDA by Timothy D. Terrell, Mises Institute
In this article by economist Jeffrey Sachs, pharmaceutical company Gilead is taken to task for selling its hepatitis C cure, Sofosbuvir (sold as Sovaldi), at a price of $84,000 per course of treatment. Sachs says that the actual production cost of Sofosbuvir is about $100.

Sachs says that Gilead is "bilking the taxpayer" by charging the . . .

SORRY!

This content is exclusively for paying members.

If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.


X
Saved Articles
X
TextTExtLInkTextTExtLInk
0